{"@id":"https://bioecon.ru/technology/in-vitro-manufactured-platelets/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://cn.bioecon.ru/technology/in-vitro-manufactured-platelets/","json":"https://cn.bioecon.ru/api/v1/technology/in-vitro-manufactured-platelets/index.json"},"id":"in-vitro-manufactured-platelets","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/pbs-biotech/","https://bioecon.ru/companies/roche-holding/","https://bioecon.ru/companies/impextraco/","https://bioecon.ru/companies/becton-dickinson/","https://bioecon.ru/companies/impacfat/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/bionet/"]},"maturity":7,"name":"体外生物反应器定向诱导人工血小板规模化制造","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"iPSC高效分化与巨核祖细胞建立"},{"n":2,"title":"仿生微流控血管剪切力反应器剥离"},{"n":3,"title":"多级切向流连续微滤纯化去核分离"},{"n":4,"title":"体外生理性活化聚集与止血功能验证"}],"summary":"通过将人诱导多能干细胞（iPSC）在体外定向多步分化为高纯度CD41+/CD42b+成熟巨核细胞，利用仿生微流控剪切力生物反应器大规模剥离无核活性血小板，制备无病原体、HLA通用的人工输注血小板。","url":"/technology/in-vitro-manufactured-platelets/","verified":"2026-11-22"}